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Abstract
Introduction: The least significant change (LSC) is a term used in individuals in order 
to evaluate whether one measurement has changed significantly from the previous 
one. It is widely used when assessing bone mineral density (BMD) scans. To the best 
of our knowledge, there no such estimate available in the literature for patients with 
disorders of calcium metabolism. Our aim was to provide an estimate of the least 
significant change for albumin-adjusted calcium in patients with normocalcaemic 
hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT).  
Methods: We used the within subject standard deviation calculated in a population of 
NPHPT and PHPT patients and multiplied it by 2.77. 
Results: The LSC for NPHPT and PHPT were found to be 0.25 and 0.24 mmol/L 
respectively (1.00 and 0.96 mg/dL). In clinical practice, the value of 0.25 mmol/L could 
be used.
Discussion: The least significant change given, could be used in two ways in these 
patients. First, it gives a range to which values are expected. This can provide some 
reassurance for the patient and the physician in cases of intermittent hypercalcaemia. 
Moreover, it can be a marker of whether an individual has an actual significant change 
of his calcium after parathyroid surgery.
Manuscript
Normocalcemic hyperparathyroidism (NPHPT) is a disorder of calcium metabolism 
which is characterised by persistently normal calcium levels and consistently elevated 
parathyroid hormone (PTH) values. According to the latest workshop on asymptomatic 
primary hyperparathyroidism (PHPT), the PTH measurement should be confirmed on 
at least two consecutive measurements, while normal calcium on several occasions. 
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Moreover, other causes of secondary hyperparathyroidism have to be excluded; these 
include medications known to affect PTH levels, low vitamin D, chronic kidney disease, 
renal calcium loss (hypercalciuria) and diseases of the gastrointestinal tract known to 
affect calcium absorption [1-3]. 
NPHPT is usually encountered during the laboratory evaluation of osteoporosis and 
has been associated with consequences known to affect patients with PHPT [4,5]. 
There has been an increasing number of studies published recently, which show a 
potential benefit of parathyroid surgery [6-10]. 
A recent study published from our group identified a number of patients with NPHPT 
in a tertiary centre and showed that patients with NPHPT usually have intermittent 
hypercalcemia, as do PHPT patients. This study supported the hypothesis that 
NPHPT is a variant of PHPT [11]. We estimated the adjusted serum calcium in these 
patients using the method of Barth et al [12] and the variability observed over time 
complicates their monitoring. According to the Fourth International Workshop on 
asymptomatic PHPT, calcium and PTH should be tested every year and if there is a 
progression to hypercalcemia, surgery could be an option [13]. However, most of these 
patients have intermittent hypercalcemia; the subsequent results might be confusing 
to whether surgery should be recommended.
The least significant change is a term used in everyday practice in order to evaluate 
whether one measurement has significant change from the previous one. It is widely 
used when assessing bone mineral density (BMD) scans. The International Society 
for Clinical Densitometry (ISCD) recommends calculating the LSC for a 95% 
confidence level, which is done by multiplying the precision error by 2.77 
(https://www.iscd.org). In the case of laboratory evaluations, this would be done by 
using the within-subject standard deviation [14]. To the best of our knowledge, there 
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no such estimate available in literature for patients with calcium metabolism disorders. 
Our aim was to provide an estimate of the least significant change in patients with 
NPHPT and PHPT.  
In our previous study we had a group of eleven NPHPT patients which were defined 
as having normal albumin-adjusted calcium and high parathyroid hormone (PTH), both 
on at least two consecutive occasions, normal estimated glomerular rate (eGFR ≥60 
ml/min/1.73m2) and vitamin D replete (≥ 50 nmol/L) on the index day [11]. For this 
population,  we used an approach described by Bland & Altman [15] to calculate the 
within-subject standard deviation and the 95% confidence intervals (CI)  for adjusted 
calcium. This was found to be 0.089 (0.080, 1.000) mmol/L [11].  In order to perform 
this analysis, the assumption that standard deviations across the subjects are similar 
should be made. However, this is not true in all clinical situations. Using a single 
“mean” within-standard deviation might underestimate the variability for some patients 
[16]. We understand that this is a limitation of this approach and that the true within-
subject SD might be bigger. A suggested approach to overcome this problem is to use 
the 90th centile of the within subject variance. This method is considered to be a 
conservative approach (Masse, 1997). This approach, would give a within-subject SD 
of 0.115 mmol/L. Therefore, the least significant changes from these estimates for 
patients with NPHPT would be 0.25 and 0.32 mmol/L respectively. 
There was a group of seventeen patients with PHPT in our study, defined as high 
albumin-adjusted calcium and high PTH on at least two consecutive occasions, having 
normal eGFR and being vitamin D replete on the index day. We excluded patients 
having familial hypocalciuric hypercalcaemia (FHH). Full details can be found in our 
study  [11]. For these patients, the respective within-subject SD was found to be 0.088 
(0.079, 0.097) [11], while when using the more conservative approach, this would be 
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0.112. Hence, the least significant changes from these estimates would be 0.24 and 
0.31 mmol/L respectively. 
The least significant change calculated in this way could be used in two ways in these 
patients. First, it gives a range to which values are expected. For example, for a patient 
with NPHPT who has a baseline adjusted calcium of 2.55 mmol/L, the LSC is 0.25 
mmol/L, so the next measurement would lie between 2.30 and 2.80 mmol/L, hence it 
is quite likely that a patient with apparent normocalcaemic hyperparathyroidism could 
have a subsequent measurement that is high, thus showing intermittent 
hypercalcaemia (11). Similarly, it is quite likely that a patient with apparent PHPT could 
have a subsequent measurement that is normal, again showing intermittent 
hypercalcaemia (Figure 1). Moreover, it can be a marker of whether an individual has 
a significant change in adjusted calcium. Following surgery for PHPT, the physician 
can make sure that there was a statistically significant drop in calcium (Error! 
Reference source not found.).
We understand that the ideal way to establish the least significant change would 
require a more strict protocol. In our previous study, patients were not fasting and the 
intervals between calcium measurements were variable, so the within-subject SD 
might not be as accurate. Moreover, the fact that we used a statistical approach to 
define our different groups might make the results specific to this population. As 
mentioned in that study, ideally, to give a more accurate estimate, a prospective 
observational study should be designed, having the same number of measurements 
for each patient at regular intervals (11). Another limitation is the lack of availability of 
ionised calcium measurements in our population. Despite these limitations, an 
approximate measure of the least significant change is provided for the first time in 
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literature and can be used in clinical practice. We believe that more studies should be 
designed to provide a more accurate estimate in the future. 
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Figure 1: The follow up measurements from a patient with normocalcaemic 
hyperparathyroidism (NPHPT, left) and primary hyperparathyroidism (PHPT, right), 
both having intermittent hypercalcaemia yet all results falling with the LSC. The  
dashed lines represent the reference interval for calcium. The gray areas represent  
the least significant change (LSC 0.25 and 0.24 mmol/L for NPHPT and PHPT 
respectively); these are given around the first available measurement of calcium. 
Adj.Ca, adjusted calcium.
Figure 1: The follow up measurements from a patient with primary 
hyperparathyroidism patient (PHPT) who had parathyroid surgery (vertical dotted line). 
The dashed lines represent the reference interval for calcium. The gray area 
represents the least significant change (LSC 0.24 mmol/L); this is given around the 
first available measurement of calcium. Adj.Ca, adjusted calcium. It can be seen that 
the postoperative calcium measurements all change by more than the LSC.
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The follow-up measurements from a patient with normocalcaemic hyperparathyroidism (NPHPT, left) and 
primary hyperparathyroidism (PHPT, right), both having intermittent hypercalcaemia yet all results falling 
within the LSC. The dashed lines represent the reference interval for calcium. The gray areas represent the 
least significant change (LSC 0.25 and 0.24 mmol/L for NPHPT and PHPT respectively); these are given 
around the first available measurement of calcium. Adj.Ca, adjusted calcium. 
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The follow-up measurements from a patient with primary hyperparathyroidism patient (PHPT) who had 
parathyroid surgery (vertical dotted line). The dashed lines represent the reference interval for calcium. The 
gray area represents the least significant change (LSC 0.24 mmol/L); this is given around the first available 
measurement of calcium. Adj.Ca, adjusted calcium. It can be seen that the postoperative calcium 
measurements all change by more than the LSC. 
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